New drug cocktails tested for Tough-to-Treat blood cancer

NCT ID NCT04722146

Summary

This early-stage study is testing the safety of a new drug called teclistamab when it is given alongside other existing myeloma medications. It involves about 140 people with multiple myeloma, including some newly diagnosed and others whose cancer has returned after prior treatments. The main goal is to find the safest and most tolerable dose combinations for future testing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Health

    Melbourne, 3004, Australia

  • CHU Nantes

    Nantes, 44093, France

  • CHU de Bordeaux - Hospital Haut-Leveque

    Pessac, 33604, France

  • Calvary Mater Newcastle Hospital

    Waratah, 2298, Australia

  • Centre Leon Berard

    Lyon, 69373, France

  • Chu Rennes Hopital Pontchaillou

    Rennes, 35000, France

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Institut Universitaire du cancer de Toulouse-Oncopole

    Toulouse, 31059, France

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10021, United States

  • St Vincents Hospital Melbourne

    Fitzroy, 3065, Australia

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • The Christie Nhs Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden NHS Trust Sutton

    Surrey, SM2 5PT, United Kingdom

  • UZ Gent

    Ghent, 9000, Belgium

  • UZA

    Edegem, 2650, Belgium

  • University College Hospital

    London, NW1 2BU, United Kingdom

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Washington University School Of Medicine

    St Louis, Missouri, 63110-1032, United States

  • Weill Cornell Medical College

    New York, New York, 10065, United States

  • Winship Cancer Institute Emory University

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.